Thyroid Eye Disease (TED): Clinical Trials

3 trials for Thyroid Eye Disease (TED), newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 recruiting. 3 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 13Recruiting 3
Phase 21Recruiting 1

Follow Thyroid Eye Disease (TED): new trials by email Literature Review of Thyroid Eye Disease (TED) trials Research Report on Thyroid Eye Disease (TED)

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Evaluation of ETHY-001 for Safety, Tolerability, and Clinical Activity in Thyroid Eye Disease
ETHY-001, Placebo - Thyroid Eye Disease (TED), Graves' Disease
Phase 1RecruitingEthyreal Bio, Inc.722026-07-062026-10-26
A Study of VV-14305 for the Treatment of Thyroid Eye Disease
VV-14305, Sham (No Treatment) - Thyroid Eye Disease (TED)
Phase 1 / Phase 2RecruitingKriya Therapeutics, Inc.1352026-05-012026-08-27
A Study of GenSci098 in Subjects With Active Thyroid Eye Disease
GenSci098, GenSci098 Placebo - Safety, Tolerability
Phase 1RecruitingChangchun GeneScience Pharmaceutical Co., Ltd.762024-09-242026-02-11

Narrower conditions

Graves Ophthalmopathy (3)  ·  Autoimmune Diseases (1)  ·  Endocrine System Diseases (1)  ·  Exophthalmos (1)  ·  Eye Diseases (1)  ·  Eye Diseases, Hereditary (1)  ·  Goiter (1)  ·  Graves Disease (1)  ·  Hyperthyroidism (1)  ·  Immune System Diseases (1)  ·  Orbital Diseases (1)  ·  Thyroid Diseases (1)

Broader conditions

Congenital, Hereditary, and Neonatal Diseases and Abnormalities (3)  ·  Genetic Diseases, Inborn (3)  ·  Autoimmune Diseases (2)  ·  Endocrine System Diseases (2)  ·  Exophthalmos (2)  ·  Eye Diseases (2)  ·  Eye Diseases, Hereditary (2)  ·  Goiter (2)  ·  Graves Disease (2)  ·  Hyperthyroidism (2)  ·  Immune System Diseases (2)  ·  Orbital Diseases (2)  ·  Thyroid Diseases (2)

Interventions

salicylhydroxamic acid (1)

Sponsors

Changchun GeneScience Pharmaceutical Co., Ltd. (1)  ·  Ethyreal Bio, Inc. (1)  ·  Kriya Therapeutics, Inc. (1)

Countries

United States (2)  ·  China (1)  ·  New Zealand (1)

Top investigators

Huifang Zhou, PHD (1)